Express Scripts (ESRX) So-Called 'Price War' Comments Taken Out of Context - Analyst (GILD) (ABBV)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
UPDATE: AbbVie Inc. (ABBV) Stock Gains
December 10, 2013 12:47 PM EST(Updated - December 10, 2013 1:00 PM EST)
AbbVie Inc. (NYSE: ABBV) stock gained ground on Tuesday. The move relates to news Express Scripts (Nasdaq: ESRX) could start a pricing war if competitors accept lower prices on Gilead's (Nasdaq:... More
Express Scripts (ESRX) Could Go With Cheaper Alternative to Gilead's (GILD) HCV Treatment
December 10, 2013 12:42 PM ESTExpress Scripts (Nasdaq: ESRX) could wage a pricing war if competitors accept lower prices on Gilead's (Nasdaq: GILD) hepatitis C (HCV) treatment.
According to Bloomberg, Express Scripts' chief medical officer, Steven Miller, commented, If... More
